Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
Codexis (NASDAQ: CDXS) has announced six presentations featuring its ECO Synthesis Platform at the upcoming TIDES USA annual meeting in San Diego from May 19-22, 2025. The company will showcase data demonstrating the scalability and reproducibility of its enzymatic siRNA manufacturing processes through two oral presentations and one poster.
Key presentations will focus on: oligonucleotide CMC for sustainable siRNA manufacturing, comparative analysis of diastereomeric distribution in siRNA synthesis, and machine learning-guided ligation fragment design. Additionally, three CDMOs will present data on Codexis' double-stranded RNA ligases, including a co-presentation with Bachem.
The company will host a conference call on May 22, 2025, at 8:00 am ET to discuss the presented data. Attendees can visit Codexis at Booth #619, with advance appointments available through their website.
Codexis (NASDAQ: CDXS) ha annunciato sei presentazioni dedicate alla sua piattaforma ECO Synthesis durante il prossimo incontro annuale TIDES USA a San Diego, dal 19 al 22 maggio 2025. L'azienda presenterà dati che dimostrano la scalabilità e la riproducibilità dei suoi processi enzimatici per la produzione di siRNA attraverso due presentazioni orali e un poster.
Le presentazioni principali si concentreranno su: CMC degli oligonucleotidi per una produzione sostenibile di siRNA, analisi comparativa della distribuzione di diastereoisomeri nella sintesi di siRNA, e progettazione di frammenti di ligazione guidata da machine learning. Inoltre, tre CDMO presenteranno dati sugli RNA ligasi a doppio filamento di Codexis, inclusa una co-presentazione con Bachem.
La società terrà una conference call il 22 maggio 2025 alle 8:00 ET per discutere i dati presentati. I partecipanti potranno visitare Codexis presso lo stand #619, con appuntamenti anticipati disponibili tramite il loro sito web.
Codexis (NASDAQ: CDXS) ha anunciado seis presentaciones que destacan su plataforma ECO Synthesis en la próxima reunión anual TIDES USA en San Diego, del 19 al 22 de mayo de 2025. La compañía mostrará datos que demuestran la escalabilidad y reproducibilidad de sus procesos enzimáticos para la fabricación de siRNA a través de dos presentaciones orales y un póster.
Las presentaciones clave se centrarán en: CMC de oligonucleótidos para una fabricación sostenible de siRNA, análisis comparativo de la distribución diastereomérica en la síntesis de siRNA y diseño de fragmentos de ligación guiado por aprendizaje automático. Además, tres CDMO presentarán datos sobre las ligasas de ARN de doble cadena de Codexis, incluyendo una co-presentación con Bachem.
La empresa realizará una llamada conferencia el 22 de mayo de 2025 a las 8:00 am ET para discutir los datos presentados. Los asistentes podrán visitar a Codexis en el stand #619, con citas previas disponibles a través de su sitio web.
Codexis (NASDAQ: CDXS)는 2025년 5월 19일부터 22일까지 샌디에이고에서 열리는 TIDES USA 연례 회의에서 ECO Synthesis 플랫폼을 주제로 한 여섯 건의 발표를 발표했습니다. 회사는 두 번의 구두 발표와 한 개의 포스터를 통해 효소 기반 siRNA 생산 공정의 확장성과 재현성을 입증하는 데이터를 선보일 예정입니다.
주요 발표 내용은 지속 가능한 siRNA 생산을 위한 올리고뉴클레오티드 CMC, siRNA 합성에서의 디아스테레오머 분포 비교 분석, 머신러닝 기반 연결 조각 설계에 중점을 둡니다. 또한 세 개의 CDMO가 Codexis의 이중 가닥 RNA 리가아제에 관한 데이터를 발표하며, Bachem과의 공동 발표도 포함됩니다.
회사는 2025년 5월 22일 오전 8시(동부시간)에 발표된 데이터를 논의하기 위한 컨퍼런스 콜을 진행할 예정입니다. 참석자들은 Codexis 부스 #619를 방문할 수 있으며, 사전 예약은 웹사이트를 통해 가능합니다.
Codexis (NASDAQ : CDXS) a annoncé six présentations mettant en avant sa plateforme ECO Synthesis lors de la prochaine réunion annuelle TIDES USA à San Diego, du 19 au 22 mai 2025. L'entreprise présentera des données démontrant la scalabilité et la reproductibilité de ses procédés enzymatiques de fabrication de siRNA à travers deux présentations orales et un poster.
Les présentations clés porteront sur : la CMC des oligonucléotides pour une fabrication durable de siRNA, l'analyse comparative de la distribution diastéréoisomérique dans la synthèse de siRNA, et la conception de fragments de ligation guidée par apprentissage automatique. De plus, trois CDMO présenteront des données sur les ligases d'ARN double brin de Codexis, incluant une co-présentation avec Bachem.
L'entreprise organisera une conférence téléphonique le 22 mai 2025 à 8h00 ET pour discuter des données présentées. Les participants pourront visiter Codexis au stand n°619, avec des rendez-vous anticipés disponibles via leur site web.
Codexis (NASDAQ: CDXS) hat sechs Präsentationen zu seiner ECO Synthesis Plattform auf dem bevorstehenden TIDES USA Jahrestreffen in San Diego vom 19. bis 22. Mai 2025 angekündigt. Das Unternehmen wird Daten präsentieren, die die Skalierbarkeit und Reproduzierbarkeit seiner enzymatischen siRNA-Herstellungsprozesse durch zwei mündliche Vorträge und ein Poster belegen.
Die Schwerpunkte der Präsentationen liegen auf: oligonukleotidischem CMC für eine nachhaltige siRNA-Produktion, vergleichender Analyse der diastereomeren Verteilung bei der siRNA-Synthese und maschinellem Lernen-gestütztem Design von Ligation-Fragmente. Zusätzlich werden drei CDMOs Daten zu Codexis' doppelsträngigen RNA-Ligasen vorstellen, darunter eine gemeinsame Präsentation mit Bachem.
Das Unternehmen wird am 22. Mai 2025 um 8:00 Uhr ET eine Telefonkonferenz abhalten, um die präsentierten Daten zu besprechen. Teilnehmer können Codexis am Stand #619 besuchen, Vorabtermine sind über die Website buchbar.
- None.
- None.
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes
Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases
Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis’ presentations will cover a range of topics, including:
- The scalability and reproducibility of ECO Synthesis manufacturing processes
- A groundbreaking machine learning tool to optimize ligase selection and fragment design
- An emerging capability to control stereochemistry during oligonucleotide synthesis
In addition, three leading contract development and manufacturing organizations (CDMOs) are presenting data on the performance of Codexis’ double-stranded RNA ligases to combine short RNA fragments, including a co-presentation by Bachem and Codexis.
Attendees of the conference may visit with the Codexis team at Booth #619 in the exhibition hall. Appointments may be made in advance via the Codexis website here.
Codexis Oral Presentations:
Main Stage Talk: Oligonucleotide CMC for Sustainable and Scalable Enzymatic siRNA Manufacturing
Date: Wednesday, May 21, 2025
Time: 9:30 am – 10:00 am PT
Codexis Speaker: Alison Moore, PhD, Chief Technical Officer
TIDES Talk: Comparative Analysis of Diastereomeric Distribution in siRNA Synthesis: Phosphoramidite Chemistry vs. Enzymatic Synthesis
Date: Wednesday, May 21, 2025
Time: 10:10 am – 10:20 am PT
Codexis Speaker: Stephanie Forget, PhD, Senior Scientist, Protein Engineering
Co-Presentation with Bachem:
Spotlight Presentation: Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments
Date: Tuesday, May 20, 2025
Time: 12:05 – 12:35 pm PT
Speakers: Arne Berthelmann, PhD, Senior Director, Oligonucleotide R&D, Bachem AG and Mathew Miller, PhD, Director, Life Sciences and RNA Technologies, Codexis
Oral presentations will take place at the Manchester Grand Hyatt San Diego in San Diego, California.
Poster Presentation:
Poster Title: Machine Learning-Guided Ligation Fragment Design for Efficient siRNA Synthesis
Time: Duration of the Conference
Location: Exhibit Hall
Codexis Presenter: Mathew Miller, PhD, Director, Life Sciences and RNA Technologies
Conference Call and Webcast
Codexis management will host a conference call beginning at 8:00 am Eastern Time on Thursday, May 22, 2025, to discuss the data presented during the conference. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A live webcast to accompany the conference call can be accessed on the Codexis Investor Relations website, where a replay will be available for 90 days. A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis™ platform, and it providing an opportunity for Codexis to efficiently capture meaningful market share; expectations regarding Codexis meeting its technical and commercial milestones regarding the ECO Synthesis™ platform; and expectations regarding the potential of and future demand for RNAi therapeutics, and whether Codexis will be able to capitalize on such demand. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop and commercialize new technology such as its ECO Synthesis™ platform and its dsRNA ligase; Codexis dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 27, 2025 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
FAQ
What will Codexis (CDXS) present at TIDES USA 2025?
When is Codexis (CDXS) hosting its conference call to discuss TIDES USA data?
What are the main topics of Codexis (CDXS) presentations at TIDES USA 2025?
Where will the TIDES USA 2025 conference featuring Codexis (CDXS) be held?
